WINTON GROUP Ltd Sells 4,139 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO)

WINTON GROUP Ltd decreased its stake in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) by 6.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 61,066 shares of the company’s stock after selling 4,139 shares during the period. WINTON GROUP Ltd’s holdings in Organogenesis were worth $171,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the stock. Acadian Asset Management LLC lifted its position in Organogenesis by 2.4% during the 2nd quarter. Acadian Asset Management LLC now owns 3,074,375 shares of the company’s stock valued at $8,605,000 after acquiring an additional 72,696 shares during the period. Allspring Global Investments Holdings LLC lifted its position in Organogenesis by 4,989.9% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 15,677 shares of the company’s stock valued at $44,000 after acquiring an additional 15,369 shares during the period. Bank of New York Mellon Corp lifted its position in Organogenesis by 9.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 393,798 shares of the company’s stock valued at $1,103,000 after acquiring an additional 33,990 shares during the period. Pallas Capital Advisors LLC purchased a new position in Organogenesis during the 2nd quarter valued at about $38,000. Finally, Assenagon Asset Management S.A. lifted its position in Organogenesis by 309.3% during the 2nd quarter. Assenagon Asset Management S.A. now owns 3,977,124 shares of the company’s stock valued at $11,136,000 after acquiring an additional 3,005,450 shares during the period. Institutional investors own 49.57% of the company’s stock.

Organogenesis Stock Down 2.1 %

Shares of Organogenesis stock opened at $2.85 on Thursday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 2.42 and a current ratio of 2.73. The stock has a market capitalization of $377.83 million, a PE ratio of 71.25 and a beta of 1.62. Organogenesis Holdings Inc. has a 52-week low of $1.96 and a 52-week high of $4.70. The company has a 50-day simple moving average of $2.80 and a two-hundred day simple moving average of $2.75.

Organogenesis (NASDAQ:ORGO) last issued its earnings results on Thursday, August 8th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.11). The firm had revenue of $130.23 million during the quarter, compared to analysts’ expectations of $122.48 million. Organogenesis had a negative return on equity of 6.03% and a negative net margin of 3.69%. On average, analysts anticipate that Organogenesis Holdings Inc. will post -0.19 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Lake Street Capital initiated coverage on shares of Organogenesis in a research report on Friday, June 28th. They set a “buy” rating and a $5.00 price target for the company.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.